Market Overview

Alonso Krangle LLP Reports Resolution of Fosamax Lawsuit Brought by Victim of Dead Jaw Syndrome


Estate of Fosamax User Who Developed Osteonecrosis of the Jaw Reaches Confidential “Stipulation Agreement” with Merck on Damages.

Melville, NY (PRWEB) October 25, 2012

The Fosamax side effect lawyers at Alonso Krangle LLP, a national law firm focused on fighting for the rights of serious personal injury victims, reports that Merck & Co. has reached a confidential “stipulation agreement” with the estate of a Fosamax user who developed Osteonecrosis of the Jaw (ONJ), or Dead Jaw Syndrome. The Fosamax side effect lawsuit, which had gone to trial twice already in the U.S. District Court, District of Southern New York, was scheduled for a third trial this month. The amount of damages Merck has agreed pay to resolve the case remains confidential. (Case No. 1:06-cv-09455).

According to court records, the original Plaintiff, a woman from Florida, had filed suit against Merck & Co. in 2009, alleging Fosamax had caused her to develop the jaw-decaying disorder, ONJ. The first trial ended in a mistrial, but the jury hearing the second trial awarded $8 million to the Plaintiff. According to a Bloomberg News report, U.S. District Judge John F. Keenen reduced that award to $1.5 million, though the Plaintiff was given the option to go to trial for a third time. The announcement of the stipulation agreement means the third trial will not go forward.
[ ]

Fosamax, marketed by Merck & Co., is an oral bisphosphonate approved to treat osteoporosis and other bone weakening diseases. Hundreds of Fosamax users have filed lawsuits in recent years alleging Fosamax caused serious side effects, including Dead Jaw Syndrome and atypical femur fractures. In addition to the Fosamax ONJ litigation underway in the Southern District of New York, hundreds of Fosamax side effect lawsuits are pending in a Mass Tort proceeding (In re: Fosamax Litigation - No. 282 NJ. Super. Ct.) in the Superior Court of New Jersey, Law Division, Atlantic County. Additional Fosamax lawsuits are pending in a multidistrict litigation in U.S. District Court, District of New Jersey before the Honorable Garrett E. Brown, Jr. (“MDL No. 2243).

In October 2010, the U.S. Food & Drug Administration (FDA) ordered the makers of Fosamax and other bisphosphonates to add information about the risk of atypical femur fractures to the “Warnings and Precautions” section of their labels. The FDA ordered the label change after a study involving over 300 women who sustained such fractures found that 94 percent had taken a bisphosphonate. Most had been on the drugs for five years or more.
[ ]

Since the FDA ordered the label change, more evidence has emerged linking long-term use of Fosamax to serious side effects. In May, an analysis published in the New England Journal of Medicine (NEJM) by FDA researchers found little benefit from the long-term use of bisphosphonates (longer than five years) due to their association with atypical thigh fractures, ONJ, and esophageal cancer.
[ ]

In June, a study published in the Archives of Internal Medicine reported that the likelihood that a patient will experience an atypical femur fracture increases the longer they use bisphosphonates like Fosamax.
[ ]

Alonso Krangle LLP offers free lawsuit evaluations to any Fosamax user who suffered a femur fracture or other side effect that could be associated with long-term use of this drug. To discuss a potential claim with one of the experienced and compassionate Fosamax femur fracture lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website,

About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website,

Alonso Krangle LLP
445 Broad Hollow Road
Suite 205
Melville, New York 11747
Toll-FREE 1-800-403-6191
Tel: 516-350-5555
Fax: 516-350-5554

For the original version on PRWeb visit:

View Comments and Join the Discussion!